2024 Nobel Prize in Chemistry Awarded to Trio for Groundbreaking Protein Research
Nobel Prize in Chemistry 2024, Protein Structure Prediction, Computational Protein Design, David Baker, Demis Hassabis, John Jumper
Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges
Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination
Pfizer CEO Albert Bourla to Engage with Activist Investor Starboard Value on Strategic Overhaul
Pfizer, Albert Bourla, Starboard Value, activist investor, pharmaceutical industry, strategic overhaul, post-COVID challenges
Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases
Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
FDA Halts Kezar’s Lupus Nephritis Trial Due to Safety Concerns Following Four Patient Deaths
FDA, Kezar Life Sciences, lupus nephritis, zetomipzomib, clinical hold, patient deaths, safety concerns
FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Ahead of Advisory Committee Meeting
FDA, Stealth BioTherapeutics, elamipretide, Barth syndrome, ultra-rare disease, advisory committee meeting, drug approval, efficacy concerns
Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy
Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction
Zealand’s Hypoglycemia Drug Faces Second FDA Rejection Due to Manufacturing Issues
Zealand Pharma, FDA rejection, dasiglucagon, congenital hyperinsulinism, hypoglycemia, CDMO inspection
FDA Raises Concerns Over Stealth BioTherapeutics’ Ultra-Rare Disease Drug Approval
Stealth BioTherapeutics, ultra-rare disease, FDA approval, Barth syndrome, elamipretide
AstraZeneca’s Airsupra Asthma Trial Halted Early Due to Overwhelming Efficacy, Paving Way for Regulatory Submission
AstraZeneca, Airsupra, asthma treatment, clinical trial, overwhelming efficacy, regulatory submission